Skip to main content Accessibility help
×
Home

High-Dose Methylprednisolone for Acute Closed Spinal Cord Injury - Only a Treatment Option

  • H. Hugenholtz (a1), D.E. Cass (a2), M.F. Dvorak (a3), D.H. Fewer (a4), R.J. Fox (a5), D.M.S. Izukawa (a6), J. Lexchin (a7), S. Tuli (a8), N. Bharatwal (a9) and C. Short (a10)...

Abstract

Background:

A systematic review of the evidence pertaining to methylprednisolone infusion following acute spinal cord injury was conducted in order to address the persistent confusion about the utility of this treatment.

Methods:

A committee of neurosurgical and orthopedic spine specialists, emergency physicians and physiatrists engaged in active clinical practice conducted an electronic database search for articles about acute spinal cord injuries and steroids, from January 1, 1966 to April 2001, that was supplemented by a manual search of reference lists, requests for unpublished additional information, translations of foreign language references and study protocols from the author of a Cochrane systematic review and Pharmacia Inc. The evidence was graded and recommendations were developed by consensus.

Results:

One hundred and fifty-seven citations that specifically addressed spinal cord injuries and methylprednisolone were retrieved and 64 reviewed. Recommendations were based on one Cochrane systematic review, six Level I clinical studies and seven Level II clinical studies that addressed changes in neurological function and complications following methylprednisolone therapy.

Conclusion:

There is insufficient evidence to support the use of high-dose methylprednisolone within eight hours following an acute closed spinal cord injury as a treatment standard or as a guideline for treatment. Methylprednisolone, prescribed as a bolus intravenous infusion of 30 mg per kilogram of body weight over fifteen minutes within eight hours of closed spinal cord injury, followed 45 minutes later by an infusion of 5.4 mg per kilogram of bodyweight per hour for 23 hours, is only a treatment option for which there is weak clinical evidence (Level I- to II-1). There is insufficient evidence to support extending methylprednisolone infusion beyond 23 hours if chosen as a treatment option.

RÉSUMÉ: Introduction:

Une revue systématique des données concernant l’infusion de méthylprednisolone suite à un traumatisme aigu de la moelle épinière a été effectuée afin de clarifier la confusion qui règne sur l’utilité de ce traitement

Méthodes:

Un comité formé de spécialistes en neurochirurgie et en chirurgie orthopédique de la colonne vertébrale, d’urgentologues et de physiatres en pratique clinique active a procédé à une recherche électronique de bases de données pour identifier des articles sur les traumatismes aigus de la moelle épinière et l’administration de stéroïdes, du 1er janvier 1966 à avril 2001. Une recherché manuelle de listes de références, la quête d’informations additionnelles non publiées, la traduction de références en langues étrangères et le protocole d’étude de l’auteur d’une Cochrane systematic review et de Pharmacia inc. ont été utilisés comme sources d’informations d’appoint. Les données ont été pondérées et des recommandations ont été développées par consensus.

Résultats:

Cent cinquante-sept citations qui traitaient spécifiquement de traumatisme de la moelle épinière et de méthylprednisolone ont été identifiées et soixante-quatre ont été revues. Les recommandations ont été basées sur une revue systématique Cochrane, six études cliniques de niveau I et sept études de niveau II qui traitaient de modifications de la function neurologique et de complications suite au traitement par la méthylprednisolone.

Conclusions:

Il n’y a pas suffisamment de données pour appuyer l’utilisation de la méthylprednisolone à haute dose en dedans de huit heures après un traumatisme aigu fermé de la moelle épinière comme traitement standard ou comme ligne directrice de traitement. La méthylprednisolone prescrite en infusion intraveineuse en bolus de 30 mg par kilogramme de poids corporel sur une période de quinze minutes en dedans de huit heures d’un traumatisme fermé de la moelle, suivie 45 minutes plus tard d’une infusion de 5,4 mg par kilogramme de poids à l’heure pendant 23 heures est seulement une option thérapeutique en faveur de laquelle il n’y a que des données cliniques faibles (Niveau I à II-1). Il n’y a pas suffisamment de données pour recommander de prolonger l’infusion de éthylprednisolone au delà de vingt-trois heures si on choisit cette option thérapeutique.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      High-Dose Methylprednisolone for Acute Closed Spinal Cord Injury - Only a Treatment Option
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      High-Dose Methylprednisolone for Acute Closed Spinal Cord Injury - Only a Treatment Option
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      High-Dose Methylprednisolone for Acute Closed Spinal Cord Injury - Only a Treatment Option
      Available formats
      ×

Copyright

References

Hide All
1. Bracken, MB, Shepard, MJ, Collins, WF, et al. A randomized,controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322(20):14051411.
2. Vandertop, WP, Notermans, NC, Algra, A. Methylprednisolone intraumatic spinal cord injuries: not proven to be beneficial to the patient at the present time. Ned Tijdschr Geneeskd 1998;142(19):10611064.
3. Coleman, WP, Benzel, D, Cahill, DW, et al. A critical appraisal of thereporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 2000;13(3):185199.
4. Hurlbert, RJ. Methylprednisolone for acute spinal cord injury: aninappropriate standard of care. J Neurosurg 2000;93(Suppl 1):17.
5. Hurlbert, RJ. The role of steroids in acute spinal cord injury. Anevidence-based analysis. Spine 2001;26(24S):S39-S46.
6. Nesathurai, S. Steroids and spinal cord injury: revisiting theNASCIS 2 and NASCIS 3 trials. J Trauma 1998;45(6):10881093.
7. Rosner, MJ. Methylprednisolone for spinal cord injury. J Neurosurg 1992;77(2):324325; discussion 325-327.
8. Short, DJ, El Masry, WS, Jones, PW. High-dose methylprednisolonein the management of acute spinal cord injury “ a systematic review from a clinical perspective. Spinal Cord 2000;38(5):273286.
9. Short, D. Use of steroids for acute spinal cord injury must bereassessed. BMJ 2000;321(7270):1224.
10. Wilkinson, HA. Spinalcord injury. J Neurosurg 2001;94(1Suppl):180181.
11. Guidelines for the management of acute cervical spine and spinalcord injuries. Section on Disorders of the Spine and Peripheral Nerves of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons. Neurosurgery 2002;50(3)Suppl:S63-S72.
12. Cook, DJ, Guyatt, GH, Laupacis, A, Sackett, DL. Rules of evidenceand clinical recommendations on the use of antithrombotic agents. Chest 1992;104(2)Suppl:305S-311S.
13. Guyatt, GH, Sackett, DL, Cook, DJ. User’s guides to the Medical Literature. JAMA 1993;270:25982601.
14. Woolf, SH, Battista, RN, Anderson, GM, Logan, AG, Wang, E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. JClin Epidemiol 1990;43(9):891905.
15. Pointillart, V, Petitjean, ME, Wiart, L, et al. Pharmacological therapyof spinal cord injury during the acute phase. Spinal Cord 2000;38(2):7176.
16. Petitjean, ME, Pointillart, V, Dixmerias, F, et al. Medical treatment ofspinal cord injury in the acute stage. Ann Fr Anesth Reanim 1998;17(2):114122.
17. Kiwerski, JE. Application of dexamethasone in the treatment ofacute spinal cord injury. Injury 1993;24(7):457460.
18. Gabler, C, Maier, R. Clinical experiences and results of high-dosagemethylprednisolone therapy in spinal cord trauma 1991 to 1993. Unfallchirurg 1995;21(1):2029.
19. Epstein, N, Hood, DC, Ransohoff, J. Gastrointestinal bleeding inpatients with spinal cord trauma. Effects of steroids, cimetidine, and mini-dose heparin. J Neurosurg 1981;54(1):1620.
20. Prendergast, MR, Saxe, JM, Ledgerwood, AM, Lucas, CE, Lucas, WF. Massive steroids do not reduce the zone of injury after penetrating spinal cord injury. J Trauma 1994;37(4):576579; discussion 579-580.
21. Levy, ML, Gans, W, Wijesinghe, HS, et al. Use of methylprednisoloneas an adjunct in the management of patients with penetrating spinal cord injury: outcome analysis. Neurosurgery 1996;39(6):11411148; discussion 1148-1149.
22. Heary, RF, Vaccaro, AR, Mesa, JJ, et al. Steroids and gunshot woundsto the spine. Neurosurgery 1997;41(3):576583; discussion 583¬584.
23. Bracken, MB. Pharmacological intervention for acute spinal cordinjury (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford: Update Software.
24. Bracken, MB. Methylprednisolone and acute spinal cord injury. Anupdate of randomized evidence. Spine 2001;26(24S):S47-S54.
25. Bracken, MB, Collins, WF, Freeman, DF, et al. Efficacy ofmethylprednisolone in acute spinal cord injury. JAMA 1984; 251(1):4552.
26. Bracken, MB, Shepard, MJ, Hellenbrand, KG, et al. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg 1985;63(5):704713.
27. Bracken, MB, Shepard, MJ, Collins, WF Jr, et al. Methylprednisoloneor naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg 1992;76(1):2331.
28. Bracken, MB, Shepard, MJ, Holford, TR, et al. Administration ofmethylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997;277(20):15971604.
29. Bracken, MB, Shepard, MJ, Holford, TR, et al. Methylprednisolone ortirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 1998;89(5):699706.
30. Matsumoto, T, Tamaki, T, Kawakami, M, et al. Early complications ofhigh-dose methylprednisolone sodium succinate treatment in the follow-upofacute cervical spinal cord injury. Spine 2001;26(4):426430.
31. Shepard, MJ, Bracken, MB. The effect of methylprednisolone,naloxone, and spinal cord trauma on four liver enzymes: observations from NASCIS 2. National Acute Spinal Cord Injury Study. Paraplegia 1994;32(4):236245.
32. Otani, K, Abe, H, Kadoya, S, et al. Beneficialeffect ofmethylprednisolone sodium succinate in the treatment of acute spinal cord injury. Sekitsui Sekizui J 1996;7:633647.
33. Poynton, AR, O’Farrell, DA, Shannon, F, et al. An evaluation of thefactors affecting neurological recovery following spinal cordinjury. Injury 1997;28(8):545548.
34. Wing, PC, Nance, P, Connell, DG, Gagnon, F. Risk of avascularnecrosis following short-term megadose methylprednisolone treatment. Spinal Cord 1998;36(9):633636.
35. Gerhart, KA, Johnson, RL, Menconi, J, Hoffman, RE, Lammertse, DP. Utilization and effectiveness of methylprednisolone in a population-based sample of spinal cord injured persons. Paraplegia 1995;33(6):316321.
36. Frankel, HL, Hancock, DO, Hyslop, G. The value of posturalreduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. Part I. Paraplegia 1969;7:179192.
37. George, ER, Scholten, DJ, Buechler, CM, et al. Failure ofmethylprednisolone to improve the outcome of spinal cord injuries. Am Surg 1995;61(8):659663; discussion 663-664.
38. Galandiuk, S, Raque, G, Appel, S, Polk, HC Jr. The two-edged swordof large-dose steroids for spinal cord trauma. Ann Surg 1993;218(4):419425; discussion 425-427.
39. Gerndt, SJ, Rodriguez, JL, Pawlik, JW, et al. Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma 1997;42(2):279284.
40. Sauerland, S, Nagelschmidt, M, Mallmann, P, Neugebauer, EAM. Risks and benefits of preoperative high-dose methylprednisolone insurgicalpatients. A systematicreview. Drug Safety 2000;23(5):449461.
41. Bedbrook, G. Recovery of spinal cord function. Paraplegia 1980;18:315323.
42. Gerhart, KA. Spinal cord injury outcomes in a population-basedsample. J Trauma 1991;31(11):15291535.
43. Waters, RL, Adkins, RH, Yakura, JS, Sie, I. Motor and sensoryrecovery following complete tetraplegia. Arch Phys Med Rehabil 1993;74(3):242247.
44. Burns, SP, Golding, DG, Rolle, WA Jr, Graziani, V, Ditunno, JF Jr. Recovery of ambulation in motor-incomplete tetraplegia. Arch Phys Med Rehabil 1997;78(11):11691172.
45. Marino, RJ, Ditunno, JF, Donovan, WH, Maynard, F Jr. Neurologicrecovery after traumatic spinal cord injury: data from the Model Spinal Cord Injury Sytems. Arch Phys Med Rehabil 1999;80(11):13911396.
46. Ditunno, JF Jr, Cohen, ME, Formal, C, Whiteneck, GG. Functionaloutcomes. In: Stover, SL, DeLisa, JA, Whiteneck, GG (Eds). Spinal Cord Injury. Clinical Outcomes from the Model Systems. Gaithersburg, Maryland: Aspen, 1995;170184.
47. Ditunno, JF Jr, Stover, SL, Freed, MM, Ahn, JH. Motor recovery of theupper extremities in traumatic quadriplegia: a multicenter study. Arch Phys Med Rehabil 1992;73(5):431436.
48. Ditunno, JF Jr. Predicting recovery after spinal cord injury: arehabilitation imperative. Arch Phys Med Rehabil 1999;80:361364.
49. Frankel, HL, Hancock, DO, Hyslop, G. The value of postural reductionin the initial management of closed injuries of the spine with paraplegia and tetraplegia. Part I. Paraplegia 1969;7:179192.
50. American Spinal Injury Association: Standards for NeurologicalClassification of Spinal Cord Patients. Chicago. American Spinal Injury Association 1992.
51. Outcomes following traumatic spinal cord injury: clinical practiceguidelines for health care professionals. Clinical Practice Guidelines, Spinal Cord Medicine 1999 July. Paralyzed Victims of America.
52. Young, W, Bracken, MB. The Second National Acute Spinal CordInjury Study. J Neurotrauma 1992;9(Suppl 1):S397-S405.
53. Bracken, MB. Treatment of acutespinalcord injury withmethylprednisolone: results of a multicenter, randomized clinical trial. J Neurotrauma 1991;8(Suppl 1):S47-50; discussion S51-S52.
54. Bracken, MB. Pharmacological treatment of acute spinal cord injury:current status and future prospects. Paraplegia 1992;30(2):102107.
55. Bracken, MB. Pharmacological treatment of acute spinal cord injury:current status and future projects. J Emerg Med 1993; 11 Suppl 1:4348.
56. Bracken, MB, Holford, TR. Effects of timing of methylprednisoloneor naloxone administration on recovery of segmental and long-tractneurologicalfunction in NASCIS 2. J Neurosurg 1993;79(4):500507.
57. Bracken, MB, Aldrich, EF, Herr, DL, et al. Clinical measurement,statistical analysis, and risk-benefit: controversies from trials of spinal injury. J Trauma 2000;48(3):558561.
58. Bracken, MB. Methylprednisolone and spinal cord injury. J Neurosurg 2000;93(Suppl 1):175179.

High-Dose Methylprednisolone for Acute Closed Spinal Cord Injury - Only a Treatment Option

  • H. Hugenholtz (a1), D.E. Cass (a2), M.F. Dvorak (a3), D.H. Fewer (a4), R.J. Fox (a5), D.M.S. Izukawa (a6), J. Lexchin (a7), S. Tuli (a8), N. Bharatwal (a9) and C. Short (a10)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed